Tech Company Financing Transactions
Pulmocide Funding Round
Pictet, Vivo Capital and Adjuvant Capital participated in a $52 million Series C funding round for Pulmocide. The round was announced on 12/6/2022.
Transaction Overview
Company Name
Announced On
12/6/2022
Transaction Type
Venture Equity
Amount
$52,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from the financing will be used to further fund clinical development, manufacturing scale-up, and preparation for potential commercialization of opelconazole. Opelconazole is a potent, novel triazole antifungal that has been specifically designed for use as an inhaled therapy against pulmonary aspergillosis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
44 Southampton Buildings
London, WC2A 1AP
UK
London, WC2A 1AP
UK
Phone
Website
Email Address
Overview
Pulmocide is a privately-held company located in London, developing novel small molecule inhaled medicines for the treatment of life threatening respiratory infections caused by RSV and Aspergillus.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Daniel Burgess
Chief Medical Officer
Lance Berman
Chief Scientific Officer
Pete Strong
VP - Bus. Development
Jennifer Cayer
VP - Operations
David Mantus
Browse more venture capital transactions:
Prev: 12/6/2022: Saporo venture capital transaction
Next: 12/7/2022: Seeds Investor venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs